Send us a text

For the last episode of season 2, Dr. Mia talks about lecanemab, a monoclonal antibody against amyloid, results since the show's most popular episode on lecanemab released on 10/7/2022.

Lecanemab or Clarity AD clinical trial results in New England Journal of Medicine (NEJM)
Death related to lecanemab, reported in Science, related to Cerebral Amyloid Angiopathy
Donanemab press release by Lilly

Key points:
1) Aducanumab approval process eroded public's trust and careful screening for patients for real-world implementation of lecanemab is needed to build back trust.
2) Actual number of patients eligible for lecanemab will be much smaller than the total number of persons living with Alzheimer's disease in the country: studies estimate anywhere from 1% to 12% of patients seen in real world clinics.  
3) Our healthcare infrastructure is not ready for early, timely, and accurate detection of Alzheimer's disease and tracking patients on monoclonal antibodies. 

Support the show

Video on Ask Dr. Mia YouTube channel
Transcripts on www.miayangmd.com. Transcripts are automatically generated and may contain minor inaccuracies.
Email: [email protected]
Opinions expressed are exclusive of Dr. Mia Yang and not reflective of her or guest speaker's employers or funders.